Covered recipient · General Payments record
SANATKUMAR D PATEL
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,094.80
- Reported across 130 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $200.80 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $132.24 | 14 |
| Merck Sharp & Dohme Corporation | $40.17 | 2 |
| Lilly USA, LLC | $28.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $28.39 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135342794 | CMS |
| Merck Sharp & Dohme LLC | $18.78 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141594068 | CMS |
| Merck Sharp & Dohme LLC | $21.39 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141953347 | CMS |
| Novo Nordisk Inc | $5.44 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097073534 | CMS |
| Novo Nordisk Inc | $4.32 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097554746 | CMS |
| Novo Nordisk Inc | $7.02 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096785825 | CMS |
| Novo Nordisk Inc | $4.41 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097654956 | CMS |
| Novo Nordisk Inc | $5.56 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096932995 | CMS |
| Novo Nordisk Inc | $24.37 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096889476 | CMS |
| Novo Nordisk Inc | $8.86 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096889644 | CMS |
| Novo Nordisk Inc | $6.56 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096572940 | CMS |
| Novo Nordisk Inc | $9.22 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096907353 | CMS |
| Novo Nordisk Inc | $10.17 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096901385 | CMS |
| Novo Nordisk Inc | $7.88 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096608648 | CMS |
| Novo Nordisk Inc | $5.56 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096926660 | CMS |
| Novo Nordisk Inc | $26.03 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096597320 | CMS |
| Novo Nordisk Inc | $6.84 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097562971 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.